The firm will test the FSHR-targeting lira-cel at up to 100-tmes higher doses after seeing better than expected outcomes at ...
Kyverna Therapeutics looks all the more likely to win the first FDA approval for a CAR-T therapy in an autoimmune disease after a registrational trial showed “highly statistically significant” ...
The latest chemistry news, including important research advances, business and policy trends, chemical safety practices, career guidance, and more. Current approved CAR T-cell therapy treatments rely ...
In a discussion hosted by Dr. Zachary Roberts, Executive Vice President of R&D and Chief Medical Officer at Allogene Therapeutics, leading rheumatologists Dr. Chris Wincup of King’s College Hospital ...
Data presented at ASH 2025 suggest earlier-line use of cilta-cel leads to better outcomes in multiple myeloma because patients have fitter immune systems and less exhausted T cells, improving CAR T ...
CAR-T Therapy continues to evolve rapidly, mRNA encoding CAR constructs directly to T cells in the bloodstream, potentially enabling CAR T cell production in the body without the need to isolate and ...
Chimeric antigen receptor (CAR) T-cell therapy has transformed the treatment of refractory or relapsed leukemia and hematologic malignancies, particularly over the past decade. Despite its ...
For decades, advanced medical breakthroughs have followed a familiar pattern: scientific discovery, clinical promise, followed at length by broad patient access–if it comes at all. Cancer treatments ...
Enabling patients to generate CAR T-cells internally could cut kidney cancer therapy costs, explained Dr. Wayne Marasco of Dana-Farber Cancer Institute. In vivo CAR T-cell therapy could drastically ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results